A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT

Clinical trial NCT07779031 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07779031
Sponsor: Liping Dou
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukaemia (AML)MDS (Myelodysplastic Syndrome)

Start date: 2025-05-01
Primary completion: 2028-04-30
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.